MedTrace Logo

Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma

NCT05221385 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-11-07

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.

Conditions

Interventions

DRUG

Gentulizumab

Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.

Sponsors & Collaborators

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jian Zhang, Doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2023-05-30
Completion
2023-10-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221385 on ClinicalTrials.gov